7-hydroxy-2-n,n-dipropylaminotetralin has been researched along with Idiopathic Parkinson Disease in 5 studies
7-hydroxy-2-N,N-dipropylaminotetralin: RN given refers to cpd without isomeric designation
| Excerpt | Relevance | Reference |
|---|---|---|
| "Pramipexole (PPX) is currently being evaluated for treatment of schizophrenia and Parkinson's disease." | 3.69 | Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist. ( Camacho-Ochoa, M; Evans, DL; Piercey, MF; Walker, EL, 1995) |
| "The role of iron in the pathogenesis of Parkinson's disease (PD) has been implicated strongly because of generation of oxidative stress leading to dopamine cell death." | 1.36 | Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto ( Antonio, T; Dutta, AK; Ghosh, B; Reith, ME, 2010) |
| "Distinguishing Alzheimer's disease from DLB is clinically relevant in terms of prognosis and appropriate treatment." | 1.30 | Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution. ( Ballard, C; Burn, D; Court, JA; Jaros, E; Johnson, M; Lloyd, S; Marshall, EF; McKeith, IG; Perry, EK; Perry, RH; Piggott, MA; Thomas, N, 1999) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 4 (80.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Ghosh, B | 1 |
| Antonio, T | 1 |
| Reith, ME | 1 |
| Dutta, AK | 1 |
| Camacho-Ochoa, M | 1 |
| Walker, EL | 1 |
| Evans, DL | 1 |
| Piercey, MF | 1 |
| Nagai, Y | 1 |
| Ueno, S | 1 |
| Saeki, Y | 1 |
| Soga, F | 1 |
| Hirano, M | 1 |
| Yanagihara, T | 1 |
| Hurley, MJ | 1 |
| Stubbs, CM | 1 |
| Jenner, P | 1 |
| Marsden, CD | 1 |
| Piggott, MA | 1 |
| Marshall, EF | 1 |
| Thomas, N | 1 |
| Lloyd, S | 1 |
| Court, JA | 1 |
| Jaros, E | 1 |
| Burn, D | 1 |
| Johnson, M | 1 |
| Perry, RH | 1 |
| McKeith, IG | 1 |
| Ballard, C | 1 |
| Perry, EK | 1 |
5 other studies available for 7-hydroxy-2-n,n-dipropylaminotetralin and Idiopathic Parkinson Disease
| Article | Year |
|---|---|
Discovery of 4-(4-(2-((5-Hydroxy-1,2,3,4-tetrahydronaphthalen-2-yl)(propyl)amino)ethyl)piperazin-1-yl)quinolin-8-ol and its analogues as highly potent dopamine D2/D3 agonists and as iron chelator: in vivo activity indicates potential application in sympto
Topics: Animals; Disease Models, Animal; Guanosine 5'-O-(3-Thiotriphosphate); Humans; Iron Chelating Agents; | 2010 |
Rat brain binding sites for pramipexole, a clinically useful D3-preferring dopamine agonist.
Topics: Animals; Autoradiography; Benzothiazoles; Binding Sites; Brain; Cloning, Molecular; Dopamine Agonist | 1995 |
Decrease of the D3 dopamine receptor mRNA expression in lymphocytes from patients with Parkinson's disease.
Topics: Actins; Aged; Base Sequence; Dopamine Agonists; Female; Gene Expression; Humans; Lymphocytes; Male; | 1996 |
D3 receptor expression within the basal ganglia is not affected by Parkinson's disease.
Topics: Aged; Aged, 80 and over; Autoradiography; Basal Ganglia; Dopamine Agonists; Female; Humans; In Situ | 1996 |
Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Autoradiography; Corpus Striatum; Dementia; Dopamine; Fe | 1999 |